Precigen’s Q1 2026 revenue rose to $23.3M, surpassing expectations as its new cancer therapy gains traction.
Precigen (PGEN) shares jumped nearly 12% Thursday after reporting Q1 2026 revenue of $23.3M, a $21.9M increase from the prior-year period. The gain was fueled by strong early sales of its newly launched cancer therapy, Papzimeos.
Analysts had anticipated a smaller revenue uptick for the quarter, though exact consensus estimates were not disclosed. The company’s performance marks a sharp turnaround from previous periods, reflecting growing adoption of its latest treatment.
The stock climbed to a three-month high, reflecting investor confidence in the therapy’s commercial potential.